CLAIMS:

1. ~~A method of inhibiting adipogenesis, said method comprising step of bringing into contact the adipocytes with~~Use of an effective amount of Calebin A in contact with adipocytes for the manufacture of a medicament for inhibiting adipogenesis.

2. ~~A method of inhibiting leptin expression in adipocytes, said method comprising step of bringing into contact the adipocytes with~~Use of an effective amount of Calebin A in contact with adipocytes for the manufacture of a medicament for inhibiting leptin expression in adipocytes.

3. ~~A method of increasing expression of adiponectin in adipocytes, said method comprising step of bringing into contact the adipocytes with~~Use of an effective amount of Calebin A in contact with adipocytes for the manufacture of a medicament for increasing expression of adiponectin in adipocytes.

4. ~~A method of inhibiting obesity induced pro-inflammatory cytokines in adipocytes, said method comprising step of bringing into contact the adipocytes with~~Use of an effective amount of Calebin A in contact with adipocytes for the manufacture of a medicament for inhibiting obesity induced pro-inflammatory cytokines in adipocytes.

5. The ~~method~~ use according to claim 4, wherein the pro-inflammatory cytokine is Tumor Necrosis Factor-α (TNF-α).

6. The ~~method~~ use according to claim 4, wherein the pro-inflammatory cytokine is Interleukin-6 (IL-6).

~~7. The method according to claims 1, 2, 3 and 4, wherein the adipocytes are human adipocytes.~~

~~8.~~7. ~~A method of reducing obesity induced systemic expression of pro-inflammatory cytokines, said method comprising step of administering~~ Use of an

effective amount of Calebin A ~~to a subject in need thereof~~ for the manufacture of a medicament for reducing obesity induced systemic expression of pro-inflammatory cytokines.

~~9.~~8. The ~~method~~ use according to claim ~~8~~ 7, wherein the pro-inflammatory cytokine is Tumor Necrosis Factor-α (TNF-α).

~~10.~~9. The ~~method~~ use according to claim ~~8~~ 7, wherein the pro-inflammatory cytokine is Interleukin-6 (IL-6).

~~11.~~10. The ~~method~~ use according to claim ~~8~~ 7, wherein the pro-inflammatory cytokine is Interleukin-1β (IL-1β).

~~12.~~11. ~~A method of obesity management, said method comprising step of administration of~~ Use of an effective amount of Calebin-A ~~to a subject in need thereof~~ for the manufacture of a medicament for obesity management.

~~13. The method as claimed in claim 8 and 12, wherein the subject is a mammal.~~

~~14. The method as claimed in claim 8 and 12, wherein the subject is a human.~~